PAREXEL EXPERTS TO ADDRESS TRENDS IN COST EFFECTIVE STUDY MANAGEMENT AND HEALTH OUTCOMES AT ISPOR ANNUAL INTERNATIONAL MEETING
Boston, MA, May 12, 2010—Experts from PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, will address key trends in late phase development, comparative effectiveness research, cost effective study management, and health outcomes at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual International Meeting. During the meeting, to be held May 15 – 19, 2010 in Atlanta, PAREXEL representatives will be in attendance to discuss expertise related to all phases of clinical development, reimbursement and market access, and medical communications. Attendees can learn more about these areas by visiting PAREXEL Booths #53 and #54 in the exhibit hall.
During the meeting, Yvonne Lis, Ph.D., Director, Health Outcomes, PAREXEL will lead the ISPOR Risk Benefit Management (RBM) Interest Group presentation “Head to Head Comparison of EMEA to U.S. RBM Guidelines Working Group,” which will be held on May 16 at 6:30 p.m. The ISPOR meeting program also features numerous poster sessions, which will be presented by PAREXEL experts, including:
- Review of Cost Effectiveness Studies in High Budget Impact Drugs – Saurabh Aggarwal, Ph.D., Senior Consultant, Reimbursement and Market Access, PAREXEL Consulting (Poster Session I: PMC16, May 17, 6:30 p.m. - 7:30 p.m.)
- Tapping Into a New Data Collection Paradigm: Using Direct to Patient Programs for More Cost Effective Study Management – Ramita Tandon, Senior Director, Global Portfolio Management, Peri-Approval Services, PAREXEL(Poster Session I: PMC39, May 17, 6:30 p.m. - 7:30 p.m.)
- A Novel Methodology for Measuring the Influence of Comorbidity in Health Outcome Studies – Victor A. Kiri, M.Sc., Ph.D., Director, Pharmacoepidemiology, Peri-Approval Services, PAREXEL (Poster Session III: PRS2, May 19, 11:45 a.m. – 12:45 p.m.)
# # #
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 54 countries around the world, and has approximately 9,500 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains “forward-looking” statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated restructuring charge of approximately $24 million over the second, third, and fourth quarters of Fiscal Year 2010; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2010 as filed with the SEC on May 7, 2010 which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.